Many of the latest therapies and medical technologies by multinational companies are having a strong presence during the ongoing China International Import Expo (CIIE), demonstrating the enterprises’ further aspirations to help Chinese patients with unmet medical needs and access to the world’s most advanced treatment solutions.
Germany-based Drager Medical Equipment, which specializes in critical care, exhibited an anesthesia workstation with ICU-level ventilation performance. It guarantees precise tidal volume delivery, active positive end-expiratory pressure, and high-trigger sensitivity for spontaneous breathing.
This equipment Atlan designed to provide a leak-tight breathing system, sample-gas recirculation function, and a heated breathing system to reduce condensation, has been widely used during the COVID-19 pandemic in the United States and Europe and is scheduled to be launched in the China market in 2021, the company said.
The machine offers a wide range of functions to help make the anesthesia process safer for both patients and healthcare workers, the company said. For example, it is equipped with smart tools to assist making informed decisions and to help avoid incorrect connection of breathing hoses with the anesthesia device leading to the inability to ventilate the patient.
French pharmaceutical company Sanofi, which aims to become the most trusted specialty care team in China by 2025, exhibited its blockbuster products, including a new oncology product treating patients with relapsed and refractory multiple myeloma and those in the rare disease field, including a first-in-class drug treating hemophilia A and B.
As a major industry player in rare disease, the company’s two main exhibits during the previous two editions of CIIE – one to treat Fabry disease and the other for mucopolysaccharidosis Type I, or MPS I, have been launched in the country.
“Six new products in the areas of atopic dermatitis, rare diseases and chronic diseases, which used to be offerings showcased at the past two years’ CIIEs to satisfy unmet needs to Chinese patients, have already been launched in China despite the COVID-19 pandemic,” said Bill Sibold, executive vice-president and head of Sanofi Genzyme.
Medtronic, an Ireland-based medical technology company, showcased at CIIE an innovative implantable cardioverter-defibrillator (ICD) to treat tachyarrhythmia and prevent sudden cardiac death as well as a cardiac pacemaker compatible with MRI screening. Data from Beijing Fuwai Hospital in 2018 showed that 540,000 individuals suffered from sudden cardiac death in China
